Innovation in Immunoassay Development 

Use of High Throughput Screening (HTS) in the process development for the IVD Industry

In the initial stages of the development of a new immunoassay, the selection of the right biomaterial as well as the definition of the formulation needs to be done in an efficient and timely way to reduce the risk in the later stages of the project where significant commitments are made and delays in the launch of the product could imply extra costs. 

Join us in the OEM series to hear how using High Throughput Screening has allowed us to evaluate more experimental conditions in an efficient way to reduce development time and de-risk in the initial stages of an immunoassay development project.